The global cardiac troponin market size was estimated to be USD 3.04 billion in 2023 and is expected to reach at USD 7.20 billion by 2034 with a CAGR of 8.16% during the forecast period 2024-2034. The escalating prevalence of cardiovascular diseases, rising adoption of point-of-care tests in hospital emergency departments, surge in the elderly population, growing advancements in technology, enhanced awareness regarding the cardiac biomarkers, a heightened demand for the treatment & management of acute & chronic health conditions particularly hypertension, heart disease, & stroke, an increasing adoption of point-of-care tests, and growing introduction of advanced cardiac troponin devices are several pivotal factors driving the growth of the market.
Growing introduction of advanced cardiac troponin devices is predicted to propel the market growth during the forecast period. Cardiac Troponin serves as a primary diagnostic indicator for identifying cardiac muscle injury. Preventing the risks of harmful consequences from a heart attack is largely dependent on the quick and precise diagnosis provided by this biomarker. Early diagnosis of myocardial infarction (MI) is aided by the identification of alterations in this protein. Consequently, industry participants are prioritizing the development and introduction of innovative products. For instance, in June 2022, SCIEX, a prominent player in life science analytical technologies and a subsidiary of Danaher Corporation, introduced the Zeno SWATH DIA, marking a notable advancement in workflows for biomarker discovery and translation.
By type, troponin I was the highest revenue-grossing segment in the global cardiac troponin market in 2023 owing to the increasing emphasis on producing cutting-edge products, such point-of-care testing devices. In predicting the risk of heart attack and cardiovascular disease, this particular form of troponin is a significant marker. Additionally, troponin T segment is predicted to grow at the fastest CAGR during the forecast period owing to the surge in regulatory approvals for troponin T kits and increasing launch of innovative devices. For instance, in July 2023, Mylab Discovery Solutions unveiled the Mybox+ diagnostic apparatus driven by optical AI engines, providing swift and precise outcomes for more than 30 diseases in clinical samples. Designed for small laboratories and centers, this portable device facilitates the examination of cardiac markers (troponin), thyroid panels (T-3, T-4, TSH), and biomarkers (CRP, D-Dimer).
By setting, laboratory testing was the highest revenue-grossing segment in the global cardiac troponin market in 2023 owing to a large number of tests conducted in lab settings. the fact that, in contrast to point-of-care diagnostics, laboratory-based testing offer more thorough analysis. These assays provide a more accurate troponin level measurement. Laboratory testing takes place at public health labs, private and commercial health labs, and labs connected to hospitals. Additionally, point-of-care (POC) testing is predicted to grow at the fastest CAGR during the forecast period owing to the increased regulatory approvals for point-of-care testing devices, expanding introduction of new products, and growing use of these tests in settings with limited resources. For instance, in January 2023, Cipla Inc, a multinational pharmaceutical company based in India, introduced a diagnostic tool named Cippoint, providing a point-of-care testing option for a range of health conditions.
By indication, acute coronary syndrome was the highest revenue-grossing segment in the global cardiac troponin market in 2023 owing to the increasing incidence of acute coronary syndrome and a heightened emphasis on the development of innovative biomarker products. Additionally, myocardial infarction is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of myocardial infarction among the elderly, an escalating demand for disease management, and an increase in the introduction of new products. For instance, in October 2022, HyTest Ltd introduced five novel antibodies designed specifically for cTnl. These offerings are applicable for the development of quantitative cTnl immunoassays.
By end-user, hospitals & clinics s was the highest revenue-grossing segment in the global cardiac troponin market in 2023 owing to the high hospital admission rate, expanding cardiovascular disease awareness, increased test usage by healthcare providers, and increasing initiatives by leading market players. For instance, in February 2023, Pathology Queensland (PQ) revealed the implementation of a new, highly sensitive cardiac troponin (hs-cTnl) assay across all Queensland Hospital laboratories in the year 2022. Additionally, diagnostic laboratories is predicted to grow at the fastest CAGR during the forecast period owing to the expanding test outsourcing operations, especially in lower income countries where cardiovascular diseases are becoming more common.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising expenditure on healthcare for supporting the cardiovascular diseases, growing prevalence of cardiovascular diseases, and increasing product approvals by regulatory bodies. For instance, in December 2022, The Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) test, designed for the Quidel Triage MeterPro platform, received approval from Health Canada. This test delivers results within approximately 20 minutes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing patient population for cardiovascular diseases, rising launch of new products, growing focus on the expansion of new product portfolios by the key operating companies, surge in awareness among the people, and rising introduction of new products. For instance, in September 2022, SRL Diagnostics unveiled "Heart Assure," a specialized test designed to anticipate the probability of a cardiac event in an individual. The high-sensitivity troponin I, a straightforward blood test, precisely forecasts the risk of cardiac injury by furnishing a heart health risk score.
Growing introduction of advanced cardiac troponin devices is predicted to propel the market growth during the forecast period. Cardiac Troponin serves as a primary diagnostic indicator for identifying cardiac muscle injury. Preventing the risks of harmful consequences from a heart attack is largely dependent on the quick and precise diagnosis provided by this biomarker. Early diagnosis of myocardial infarction (MI) is aided by the identification of alterations in this protein. Consequently, industry participants are prioritizing the development and introduction of innovative products. For instance, in June 2022, SCIEX, a prominent player in life science analytical technologies and a subsidiary of Danaher Corporation, introduced the Zeno SWATH DIA, marking a notable advancement in workflows for biomarker discovery and translation.
By type, troponin I was the highest revenue-grossing segment in the global cardiac troponin market in 2023 owing to the increasing emphasis on producing cutting-edge products, such point-of-care testing devices. In predicting the risk of heart attack and cardiovascular disease, this particular form of troponin is a significant marker. Additionally, troponin T segment is predicted to grow at the fastest CAGR during the forecast period owing to the surge in regulatory approvals for troponin T kits and increasing launch of innovative devices. For instance, in July 2023, Mylab Discovery Solutions unveiled the Mybox+ diagnostic apparatus driven by optical AI engines, providing swift and precise outcomes for more than 30 diseases in clinical samples. Designed for small laboratories and centers, this portable device facilitates the examination of cardiac markers (troponin), thyroid panels (T-3, T-4, TSH), and biomarkers (CRP, D-Dimer).
By setting, laboratory testing was the highest revenue-grossing segment in the global cardiac troponin market in 2023 owing to a large number of tests conducted in lab settings. the fact that, in contrast to point-of-care diagnostics, laboratory-based testing offer more thorough analysis. These assays provide a more accurate troponin level measurement. Laboratory testing takes place at public health labs, private and commercial health labs, and labs connected to hospitals. Additionally, point-of-care (POC) testing is predicted to grow at the fastest CAGR during the forecast period owing to the increased regulatory approvals for point-of-care testing devices, expanding introduction of new products, and growing use of these tests in settings with limited resources. For instance, in January 2023, Cipla Inc, a multinational pharmaceutical company based in India, introduced a diagnostic tool named Cippoint, providing a point-of-care testing option for a range of health conditions.
By indication, acute coronary syndrome was the highest revenue-grossing segment in the global cardiac troponin market in 2023 owing to the increasing incidence of acute coronary syndrome and a heightened emphasis on the development of innovative biomarker products. Additionally, myocardial infarction is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of myocardial infarction among the elderly, an escalating demand for disease management, and an increase in the introduction of new products. For instance, in October 2022, HyTest Ltd introduced five novel antibodies designed specifically for cTnl. These offerings are applicable for the development of quantitative cTnl immunoassays.
By end-user, hospitals & clinics s was the highest revenue-grossing segment in the global cardiac troponin market in 2023 owing to the high hospital admission rate, expanding cardiovascular disease awareness, increased test usage by healthcare providers, and increasing initiatives by leading market players. For instance, in February 2023, Pathology Queensland (PQ) revealed the implementation of a new, highly sensitive cardiac troponin (hs-cTnl) assay across all Queensland Hospital laboratories in the year 2022. Additionally, diagnostic laboratories is predicted to grow at the fastest CAGR during the forecast period owing to the expanding test outsourcing operations, especially in lower income countries where cardiovascular diseases are becoming more common.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising expenditure on healthcare for supporting the cardiovascular diseases, growing prevalence of cardiovascular diseases, and increasing product approvals by regulatory bodies. For instance, in December 2022, The Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) test, designed for the Quidel Triage MeterPro platform, received approval from Health Canada. This test delivers results within approximately 20 minutes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing patient population for cardiovascular diseases, rising launch of new products, growing focus on the expansion of new product portfolios by the key operating companies, surge in awareness among the people, and rising introduction of new products. For instance, in September 2022, SRL Diagnostics unveiled "Heart Assure," a specialized test designed to anticipate the probability of a cardiac event in an individual. The high-sensitivity troponin I, a straightforward blood test, precisely forecasts the risk of cardiac injury by furnishing a heart health risk score.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Cardiac Troponin Market Report 2023 - 2034
Cardiac Troponin Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Troponin I
- Troponin T
Cardiac Troponin Market Analysis & Forecast by Setting 2023 - 2034 (Revenue USD Bn)
- Point-Of-Care (POC) Testing
- Laboratory Testing
Cardiac Troponin Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Acute Coronary Syndrome
- Congestive Heart Failure
- Myocardial Infarction
- Others
Cardiac Troponin Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Diagnostic Laboratories
- Hospitals & Clinics
- Homecare Settings & Others
Cardiac Troponin Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cardiac Troponin Market: Type Estimates & Trend Analysis
8. Cardiac Troponin Market: Setting Estimates & Trend Analysis
9. Cardiac Troponin Market: Indication Estimates & Trend Analysis
10. Cardiac Troponin Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Cardiac Troponin Market
13. Europe Cardiac Troponin Market
14. Asia Pacific Cardiac Troponin Market
15. Latin America Cardiac Troponin Market
16. MEA Cardiac Troponin Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- QuidelOrtho (Quidel Corporation)
- bioMerieux SA
- Beckman Coulter Inc. (Danaher)
- PerkinElmer Inc
- Siemens Healthineers AG
- LifeSign LLC.
- Eurolyser Diagnostica GmbH
- F. Hoffmann-La Roche Ltd.
- Abbott
- RESPONSE BIOMEDICAL
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.04 Billion |
| Forecasted Market Value ( USD | $ 7.2 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
